Merck & Co Inc (MRK)

MRK (:Drugs) EQUITY
$54.84
pos +0.00
+0.00%
Today's Range: 54.56 - 55.64 | MRK Avg Daily Volume: 9,896,500
Last Update: 04/29/16 - 4:01 PM EDT
Volume: 0
YTD Performance: 0.00%
Open: $0.00
Previous Close: $55.74
52 Week Range: $45.69 - $61.70
Oustanding Shares: 2,775,258,591
Market Cap: 154,692,913,862
6-Month Chart
TheStreet Ratings Grade for MRK
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 5 6 6 7
Moderate Buy 0 0 0 0
Hold 7 7 7 7
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.17 2.08 2.08 2.00
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 0.00
Price Earnings Comparisons:
MRK Sector Avg. S&P 500
0.00 35.70 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
0.00% 0.00% 0.00%
GROWTH 12 Mo 3 Yr CAGR
Revenue -6.50 -0.20 -0.06
Net Income -62.60 -0.30 -0.11
EPS -61.60 -0.20 -0.08
Earnings for MRK:
EBITDA 13.92B
Revenue 39.50B
Average Earnings Estimates
Qtr (03/16) Qtr (06/16) FY (12/16) FY (12/17)
Average Estimate $0.85 $0.91 $3.71 $3.71
Number of Analysts 9 6 9 9
High Estimate $0.90 $0.93 $3.75 $3.88
Low Estimate $0.82 $0.88 $3.63 $3.48
Prior Year $0.85 $0.86 $3.59 $3.71
Growth Rate (Year over Year) 0.52% 5.81% 3.22% 0.21%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
By

David Katz

 | Apr 20, 2016 | 7:00 AM EDT

Candidates have decried rising drug and medical prices, but there are reasons to like these stocks.

bullishMerck rated new Buy at SocGen

Apr 7, 2016 | 7:45 AM EDT

MRK was initiated with a Buy rating, Societe Generale said. Valuation call, based on an $80 price target. 

By

Jim Cramer

 | Apr 5, 2016 | 11:24 AM EDT

Plus, the bears know where to lurk after a run.

By

Gary Morrow

 | Apr 4, 2016 | 3:00 PM EDT

Shares are set up well for more upside as they begin to put distance on what now appears to be a major double bottom.

By

Timothy Collins

 | Mar 28, 2016 | 12:35 PM EDT

Following a brief selloff on Hep-C drug dispute outcome, GILD looks interesting on the upside.

By

Dick Arms

 | Mar 15, 2016 | 7:00 AM EDT

The Russell 2000's failure to follow the S&P and Dow's lead is only one reason for concern.

By

Dick Arms

 | Feb 23, 2016 | 7:00 AM EST

However, longer-term investors should be ready to take profits as the market nears resistance levels.

By

David Katz

 | Feb 12, 2016 | 7:00 AM EST

The electrics have been crackling, but the group has more downside risk than currently perceived.

By

Bret Jensen

 | Feb 2, 2016 | 9:00 AM EST

In a year's time, investors may look back and think this was a great entry point.

By

Jim Cramer

 | Feb 1, 2016 | 10:35 AM EST

Jim Cramer says healthcare companies will be in the spotlight this week and investors should take a long term view of the sector if the stocks selloff.

Mine and many other reviews of the meeting coming Monday, but the quick highlights to whet...

Up in an hour or so!

Enjoy your weekend and thanks for reading my Diary.

HIG, the object of my affection today, rips +$0.50 higher in the last few minutes of tradi...
Rolling SDS long sale proceeds into SPY/QQQ $2.5 billion to buy at month end, aiding marke...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.